Barclays PLC Purchases 84,118 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Barclays PLC raised its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 103.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,449 shares of the company's stock after acquiring an additional 84,118 shares during the period. Barclays PLC owned approximately 0.18% of Scholar Rock worth $1,324,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of SRRK. Geode Capital Management LLC grew its position in Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after buying an additional 120,489 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Scholar Rock by 16.2% in the third quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock valued at $1,600,000 after acquiring an additional 27,801 shares in the last quarter. Sphera Funds Management LTD. acquired a new position in shares of Scholar Rock during the third quarter valued at approximately $1,337,000. Quarry LP raised its holdings in Scholar Rock by 3,443.3% during the third quarter. Quarry LP now owns 4,500 shares of the company's stock worth $36,000 after purchasing an additional 4,373 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Scholar Rock by 249.7% in the third quarter. Point72 Asset Management L.P. now owns 28,649 shares of the company's stock worth $229,000 after purchasing an additional 20,456 shares during the period. Institutional investors own 91.08% of the company's stock.

Insider Activity

In related news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the company's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $38.49, for a total transaction of $15,759,076.17. Following the transaction, the insider now directly owns 10,850,005 shares of the company's stock, valued at approximately $417,616,692.45. This represents a 3.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.20% of the stock is currently owned by company insiders.

Scholar Rock Price Performance

Shares of NASDAQ:SRRK opened at $40.49 on Monday. The stock has a market capitalization of $3.79 billion, a P/E ratio of -17.23 and a beta of 0.52. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The business has a 50-day moving average of $37.85 and a two-hundred day moving average of $21.84.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. HC Wainwright boosted their price objective on Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Piper Sandler boosted their target price on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an "overweight" rating in a report on Tuesday, October 15th. Wedbush restated an "outperform" rating and set a $47.00 target price on shares of Scholar Rock in a report on Thursday. BMO Capital Markets upped their price target on Scholar Rock from $34.00 to $38.00 and gave the company an "outperform" rating in a report on Friday, October 11th. Finally, JPMorgan Chase & Co. raised their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a research note on Monday, October 14th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Scholar Rock presently has a consensus rating of "Buy" and a consensus target price of $40.43.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.